Pharmaceuticals, Biotechnology and Life Sciences
Here’s a lightly edited version of the interview with Dr. Joseph Gulfo, the executive director of the Lewis Center for Healthcare Innovation and Technology at Fairleigh Dickinson University, the author of “Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances” and the former President and CEO of the medical device firm MELA Sciences:
Onxeo S.A., a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular…
NeuroVive Pharmaceutical will redirect its Taiwan-based subsidiary’s research resources and activities to the parent company NeuroVive Pharmaceutical.
ImmuPharma has provided details of patient recruitment into its pivotal 52-week Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupus.
Beximco Pharmaceuticals has went overseas to form a joint venture (JV) with a Malaysia-based BioCare Manufacturing. This is the Bangladesh’s company’s first such JV.
Vectura Group has triggered milestone receipt of $5 million from Novartis by reaching $512 million combined net sales of Seebri,…
Neovacs’s Scientific Advisory Board has recommended extension of the development of IFN Kinoid to a new indication, Type 1 Diabetes, with the objectives of obtaining preclinical proof of concept in 2017 and initiating clinical development for this program in the first half of 2018.
Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround
TxCell has moved into action to raise some money, as it wants to raise gross proceeds of about €11 million by issuing new shares with warrants attached.
The deal InnovaDerma had with PROS International Company of Korea to sell InnovaDerma products in a terrotiroy of S Korea, Japan, China and Russia has breaken apart, the UK based maker of hair and skin care products said on Wednesday.